Finanzen von Nanovibronix Inc (NAOV)NAOVNanovibronix Inc

Nanovibronix Inc (NAOV) generates its revenue primarily from Biological device, which accounts for 100.0% of total sales, equivalent to $494.00K. Understanding this concentration is critical for investors evaluating how NAOV navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Nanovibronix Inc maintains a gross margin of 26.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -311.22%, while the net margin is 70.64%. These profitability ratios, combined with a Return on Equity (ROE) of -20.67%, provide a clear picture of how effectively NAOV converts its operational activities into shareholder value.

In the context of the broader market, NAOV competes directly with industry leaders such as NUWE and VTAK. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NAOV's gross margin of 26.18% stands against NUWE's 76.08% and VTAK's 90.28%. Such benchmarking helps identify whether Nanovibronix Inc is trading at a premium or discount relative to its financial performance.